{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:49:20Z","timestamp":1790243360833,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.6269","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T15:01:39Z","timestamp":1649257299000},"page":"e226269","source":"Crossref","is-referenced-by-count":59,"title":["Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization"],"prefix":"10.1001","volume":"5","author":[{"given":"Todd C.","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Vigod","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto and Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9milie","family":"Bortolussi-Courval","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hanula","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Boulware","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Reiersen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"issue":"8","key":"zoi220197r1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial.","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann Intern Med"},{"key":"zoi220197r2","article-title":"Inhaled and intranasal ciclesonide for the treatment of COVID-19 in adult outpatients: CONTAIN phase II randomised controlled trial.","volume":"375","author":"Ezer","year":"2021","journal-title":"BMJ"},{"key":"zoi220197r3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","article-title":"Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells.","volume":"727","author":"Ishima","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"zoi220197r4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19.","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front Pharmacol"},{"issue":"478","key":"zoi220197r5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis.","volume":"11","author":"Rosen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"22","key":"zoi220197r6","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial.","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"zoi220197r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofab050","article-title":"Prospective Cohort of fluvoxamine for early treatment of coronavirus disease 19.","volume":"8","author":"Seftel","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"zoi220197r8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33090","article-title":"Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants.","volume":"4","author":"Oskotsky","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi220197r10","first-page":"e24","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.","volume":"10","author":"Reis","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"71","key":"zoi220197r12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"zoi220197r13","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R Package.","volume":"1","author":"R\u00f6ver","year":"2020","journal-title":"J Stat Softw"},{"issue":"3","key":"zoi220197r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"5","key":"zoi220197r16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1164\/rccm.202006-2381CP","article-title":"Using bayesian methods to augment the interpretation of critical care trials: an overview of theory and example reanalysis of the alveolar recruitment for acute respiratory distress syndrome trial.","volume":"203","author":"Zampieri","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"zoi220197r17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.v34.6","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in bayesian meta-analysis.","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"issue":"1","key":"zoi220197r18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1536867X0800800102","article-title":"Metan: fixed- and random-effects meta-analysis.","volume":"8","author":"Harris","year":"2008","journal-title":"Stata J"},{"key":"zoi220197r19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ijid.2021.01.065","article-title":"Remdesivir and systemic corticosteroids for the treatment of COVID-19: a bayesian re-analysis.","volume":"104","author":"Lee","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"7650","key":"zoi220197r20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"14","key":"zoi220197r28","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial.","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"key":"zoi220197r9","unstructured":"Lenze? E. Fluvoxamine for early treatment of COVID-19: a fully-remote, randomized placebo controlled trial. ClinicalTrials.gov; 2021. Accessed November 15, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04668950"},{"key":"zoi220197r11","unstructured":"Lenze? EJ. August 20, 2021: Fluvoxamine for early treatment of covid-19: the STOP COVID clinical trials. Rethinking Clinical Trials. Published August 24, 2021. Accessed November 1, 2021. https:\/\/rethinkingclinicaltrials.org\/news\/august-20-2021-fluvoxamine-for-early-treatment-of-covid-19-the-stop-covid-clinical-trials-eric-lenze-md\/"},{"key":"zoi220197r15","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Published 2019. Accessed March 3, 2022. https:\/\/www.R-project.org"},{"key":"zoi220197r21","unstructured":"University of Minnesota. COVID-OUT: early outpatient treatment for SARS-CoV-2 infection (COVID-19). ClinicalTrials.gov; 2022. Accessed February 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510194"},{"key":"zoi220197r22","unstructured":"SigmaDrugs Research Ltd. A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patients. ClinicalTrials.gov; 2021. Accessed February 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04718480"},{"key":"zoi220197r23","unstructured":"Naggie? S. ACTIV-6: COVID-19 outpatient randomized trial to evaluate efficacy of repurposed medications. ClinicalTrials.gov; 2021. Accessed February 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04885530"},{"key":"zoi220197r24","unstructured":"Wannigama? DL. Randomized-controlled trial of the effectiveness of COVID-19 early treatment in community with fluvoxamine, bromhexine, cyproheptadine, and niclosamide in decreasing recovery time. ClinicalTrials.gov; 2022. Accessed February 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05087381"},{"key":"zoi220197r25","unstructured":"Safa? M. Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward. Accessed November 12, 2021. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20131115015405N4"},{"key":"zoi220197r26","unstructured":"Chong? YP. Fluvoxamine for adults with mild to moderate COVID-19: a single-blind, randomized, placebo-controlled trial. ClinicalTrials.gov; 2021. Accessed November 12, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04711863"},{"key":"zoi220197r27","unstructured":"Siripongboonsitti? T. Effect of combined fluvoxamine with favipiravir versus favipiravir monotherapy in prevention of clinical deterioration among mild to moderate COVID-19 patients monitoring by telemedicine in virtual clinic: open-label randomized controlled trial. World Health Organization; 2021. Accessed November 12, 2021. https:\/\/trialsearch.who.int\/?TrialID=TCTR20210615002"},{"key":"zoi220197r29","unstructured":"Bhimraj? A, Morgan? R, Hirsch Shumaker? A, . Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19 version 5.5.2. Infectious Diseases Society of America. Published January 12, 2022. Accessed January 14, 2022. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/"},{"key":"zoi220197r30","unstructured":"List of medications, September 29, 2021. R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec. Published October 1, 2021. Accessed October 27, 2021. https:\/\/www.ramq.gouv.qc.ca\/en\/media\/12091"},{"key":"zoi220197r31","unstructured":"Fluvoxamine Prices. GoodRx. Accessed November 8, 2021. https:\/\/www.goodrx.com\/fluvoxamine"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2790742\/lee_2022_oi_220197_1648495732.56746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T15:01:54Z","timestamp":1649257314000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2790742"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.6269","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}